High-Risk Population Pathways
Explore how pathway value changes for populations where missed or delayed iron deficiency may carry higher clinical and economic burden.
Preferred pathway
Aggressive detection and faster treatment
Patients detected
1,092
Patients missed
108
Patients treated
1,092
Patients responding
961
Total pathway cost
$2.40M
Cost per successful treatment
$2,493
ICER vs conservative
$30,439 / QALY
Cohort trace
| Pathway | Cohort | ID cases | Detected | Missed | Treated | Responders | Escalated IV | Total cost | QALYs | NMB | Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Conservative pathway | 10,000 | 1,200 | 660 | 540 | 660 | 383 | 53 | $990,076 | -2.46 | -$1.24M | Dominated |
| Guideline-informed risk-based pathway | 10,000 | 1,200 | 984 | 216 | 984 | 768 | 187 | $1.34M | 29.74 | $1.63M | Requires review |
| Aggressive detection and faster treatment | 10,000 | 1,200 | 1,092 | 108 | 1,092 | 961 | 442 | $2.40M | 43.73 | $1.98M | Preferred |
Patient pathway funnel — Aggressive detection and faster treatment
Detected vs missed by pathway
Cost breakdown
Treatment mix by pathway
Net monetary benefit comparison
Interpretation
For General US adults at Moderate risk, the Aggressive detection and faster treatment produces the highest net monetary benefit in this illustrative model. The result is influenced by detection rate (91% of true cases), reduced missed-diagnosis costs, and treatment mix balance, partially offset by increased testing and treatment intensity.
Results are generated from an illustrative demonstration model and should not be interpreted as final clinical, policy, or economic conclusions.